@article {Kitamura1407, author = {M Kitamura and N Kitaichi and M Takeuchi and H Kitamei and K Namba and S-i Yamagishi and K Iwabuchi and K Ono{\'e} and S Ohno}, title = {Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease}, volume = {89}, number = {11}, pages = {1407--1409}, year = {2005}, doi = {10.1136/bjo.2005.072678}, publisher = {BMJ Publishing Group Ltd}, abstract = {Background/aims: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease. Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody. Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p\<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p\<0.001). Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/89/11/1407}, eprint = {https://bjo.bmj.com/content/89/11/1407.full.pdf}, journal = {British Journal of Ophthalmology} }